IP Library Granted Patent US 11,517,555
Granted Patent B2
US 11,517,555 · App. 15/756,286 · Granted Dec 6, 2022

Solid soluble ferric pyrophosphate formulations, kits, and methods using the same

Inventors: Robert Chioini (Wixom, MI); Ajay Gupta (Las Vegas, NV)
Assignee: Rockwell Medical, Inc.
A61K31/295A61K9/1611A61K9/1623A61K9/1688A61M1/1666A61M1/287A61M2202/064
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,517,555
App. No.
15/756,286
Granted
Dec 6, 2022
Kind
B2
Abstract

A solid particulate formulation comprising soluble ferric pyrophosphate and a sachet comprising the solid particulate formulation of soluble ferric pyrophosphate for adding to a dialysis solution are provided. Improved methods of administering soluble ferric pyrophosphate comprising the solid particulate formulations and kits comprising the solid particulate formulation and a dialysis concentrate formulation are also disclosed.

Claims (24)

1. A solid particulate formulation of soluble ferric pyrophosphate citrate chelate comprising milled soluble ferric pyrophosphate wherein 90% of the particles have a particle size between 1 μm and 50 μm.

2. The solid particulate formulation of claim 1 , wherein the soluble ferric pyrophosphate citrate chelate has an angle of repose less than 45 degrees.

3. The solid particulate formulation of claim 1 that is stable in aqueous solution at ambient temperature for at least 24 months.

4. The solid particulate formulation of claim 1 , wherein the soluble ferric pyrophosphate citrate chelate comprises iron in an amount of 7% to 11% by weight, citrate in an amount of at least 14%, and pyrophosphate in an amount of at least 10%.

5. The solid particulate formulation of claim 1 , comprising iron in an amount from 7.5-9.0% by weight, citrate in an amount from 15-22% by weight, pyrophosphate in an amount from 15-22% by weight, phosphate in an amount less than 2%, sodium in an amount from 18-25% by weight, and sulfate in an amount from 20-35% by weight.

6. The solid particulate formulation of claim 1 , comprising iron in an amount from 9-14% by weight, citrate in an amount from 30-60% by weight, pyrophosphate in an amount from 5-20% by weight, sodium in an amount from 1-15% by weight, and essentially no sulfate.

7. The solid particulate formulation of claim 1 , comprising a compound having structure (I):

8. The solid particulate formulation of claim 1 , wherein the soluble ferric pyrophosphate citrate chelate has an angle of repose less than 42 degrees.

9. The solid particulate formulation of claim 1 , wherein 90% of the particles have a particle size between 3 μm and 40 μm.

10. The solid particulate formulation of claim 1 , wherein 90% of the particles have a particle size between 10 μm and 30 μm.

11. The solid particulate formulation of claim 1 , wherein 90% of the particles have a particle size between 1 μm and 25 μm.

12. A sachet comprising the solid particulate formulation of claim 1 .

13. The sachet of claim 12 , comprising a dose of soluble ferric pyrophosphate citrate chelate that will result in a final iron concentration of 110 μg/L or 2 μM in a dialysate to be administered to a patient receiving hemodialysis.

14. A kit comprising the solid particulate formulation of claim 1 and a dialysis concentrate formulation in a solid or liquid form.

15. The kit of claim 14 , wherein the dialysis concentrate formulation is a solid form.

16. The kit of claim 14 , wherein the dialysis concentrate formulation is a liquid form.

17. The kit of claim 14 , wherein the dialysis concentrate formulation is an acid.

18. The kit of claim 14 , wherein the dialysis concentrate formulation is a base.

19. A composition comprising particles of a soluble ferric pyrophosphate citrate chelate, comprising 90% of the particles having a particle size between 1 μm and 50 μm.

20. The composition of claim 19 , wherein the soluble ferric pyrophosphate citrate chelate has an angle of repose less than 45 degrees.

21. The composition of claim 19 , wherein the soluble ferric pyrophosphate citrate chelate has an angle of repose less than 42 degrees.

22. The composition of claim 19 , wherein the soluble ferric pyrophosphate citrate chelate comprises iron in an amount of 7% to 11% by weight, citrate in an amount of at least 14%, and pyrophosphate in an amount of at least 10%.

23. The composition of claim 19 , comprising iron in an amount from 7.5-9.0% by weight, citrate in an amount from 15-22% by weight, pyrophosphate in an amount from 15-22% by weight, phosphate in an amount less than 2%, sodium in an amount from 18-25% by weight, and sulfate in an amount from 20-35% by weight.

24. The composition of claim 19 , comprising iron in an amount from 9-14% by weight, citrate in an amount from 30-60% by weight, pyrophosphate in an amount from 5-20% by weight, sodium in an amount from 1-15% by weight, and essentially no sulfate.

Assignments (2)
SECURITY INTEREST Recorded May 6, 2020
From: ROCKWELL MEDICAL, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 052584/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: GUPTA, AJAY; CHIOINI, ROBERT
To: ROCKWELL MEDICAL, INC.
Reel/Frame 047957/0487 →
Continuity (2)
Provisional Application 62214908 · Sep 4, 2015
Related Publication 20180243256A1 · Aug 30, 2018